Loading...

SCNT

PG

ASCENTAGE PHARMA GROUP INTERNATIONAL

(AAPG)

2025 6-K

Business Relocation

1 Apr '26

Financial Results Update

26 Mar '26

Research Presentation

18 Mar '26

Board Meeting Notice

16 Mar '26

Financial Update Notice

11 Mar '26

Investor Conferences

23 Feb '26

Biotech Summit Participation

9 Feb '26

FDA Clearance Announcement

6 Feb '26

Global Innovation Strategy

15 Jan '26

FDA Approval Announcement

7 Jan '26

Management Changes

31 Dec '25

J.P. Morgan Conference

17 Dec '25

Press Releases Update

9 Dec '25

Pivotal Study Data

8 Dec '25

FDA Approval Announcement

5 Dec '25

Key Data Webcast

1 Dec '25

Awards Announcement

28 Nov '25

Clinical Data Release

25 Nov '25

Investor Conferences Announ...

19 Nov '25

Clinical Presentations

4 Nov '25

Investor Conferences

30 Oct '25

Investor Conference Partici...

7 Oct '25

Investor Conference Partici...

28 Aug '25

Interim Results Reported

21 Aug '25

Phase III Trial Update

18 Aug '25

Board Meeting Notice

8 Aug '25

Corporate Update

7 Aug '25

Biotech Summit Participation

31 Jul '25

Share Placement Update

25 Jul '25

Placement Shares Closure

17 Jul '25

Share Placement Agreement

14 Jul '25

Approval Announcement

10 Jul '25

Management Changes

8 Jul '25

Awards Announcement

27 Jun '25

Clinical Study Results

16 Jun '25

Study Presentations

9 Jun '25

Clinical Data Release

2 Jun '25

Clinical Data Release

23 May '25

Meeting Results Report

20 May '25

Research Presentation

28 Apr '25

Clinical Data Presentation

24 Apr '25

Guideline Inclusion Announc...

21 Apr '25

Annual Meeting Notice

16 Apr '25

Stock Purchase Announcement

8 Apr '25

Share Purchase Announcement

31 Mar '25

Annual Results Announced

27 Mar '25

Filing Amendment

26 Mar '25

Research Presentation

25 Mar '25

Upcoming Financial Results

12 Mar '25

Therapy Designation Granted

5 Mar '25

Company Secretary Change

25 Feb '25

Stock Offering Update

14 Feb '25

Partial Over-allotment

10 Feb '25

External Links:

SEC

On June 9, 2025, Ascentage Pharma Group announced that thirteen of its studies, including those on Olverembatinib and Lisaftoclax, have been selected for presentation at the 2025 European Hematology Association Annual Congress. This event is important for the company as it highlights their advancements in research and development.

AI Assistant

ASCENTAGE PHARMA GROUP INTERNATIONAL

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.